• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Quotient Limited

    6/26/23 5:21:47 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QTNT alert in real time by email
    POS AM 1 qtntq20230626i_posam.htm FORM POS AM qtntq20230626i_posam.htm

    P

     

    As filed with the Securities and Exchange Commission on June 26, 2023

     

    Registration No. 333-267190

    Registration No. 333-261357

    Registration No. 333-257772

    Registration No. 333-248235

    Registration No. 333-235508

    Registration No. 333-226800

    Registration No. 333-221470

    Registration No. 333-203818

     

     

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

     

     

    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No.              333-267190

    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No.              333-261357

    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No.              333-257772

    Post-Effective Amendment No. 2 to Form S-3 Registration Statement No.              333-248235

    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No.              333-235508

    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No.              333-226800

    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No.              333-221470

    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No.              333-203818

     

    UNDER
    THE SECURITIES ACT OF 1933

     

     

     

     

     

    QUOTIENT LIMITED

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

     

    Jersey, Channel Islands

    Not Applicable

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification Number)

       
       

    001-36415

    (Commission File Number)

    Business Park Terre Bonne,

    Route de Crassier 13,

    1262 Eysins, Switzerland

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Not applicable

    (Zip Code)

    Registrant's telephone number, including area code: 011-41-22-716-9800

     

     

     

    n/a
    (Former name or former address, if changed since last report)

     

     

     

    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.

     

     

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

     

     

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

     

     

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

     

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

     

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

     

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

    Large accelerated filer

     

    ☐

     

    Accelerated filer

     

    ☐

    Non-accelerated filer

     

    ☒

     

    Smaller reporting company

     

    ☒

           

    Emerging growth company

     

    ☐

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

         

    DEREGISTRATION OF SECURITIES

     

    These Post-Effective Amendments relate to the following Registration Statements on Form S-3 (the “Registration Statements”) filed by Quotient Limited (the “Registrant” or the “Company”) with the Securities and Exchange Commission (the “SEC”):

     

     

    1.

    Registration Statement on Form S-3 (File No. 333-267190), originally filed with the SEC on August 31, 2022, registering 8,494,595 shares of the Company’s ordinary shares, nil par value per share (the “Ordinary Shares”).

     

     

    2.

    Registration Statement on Form S-3 (File No. 333-261357), originally filed with the SEC on November 24, 2021, registering 2,776,792 Ordinary Shares.

     

     

    3.

    Registration Statement on Form S-3 (File No. 333- 257772), originally filed with the SEC on July 8, 2021, registering 18,518,514 Ordinary Shares issuable upon conversion of certain convertible notes.

     

     

    4.

    Registration Statement on Form S-3 (File No. 333-248235), originally filed with the SEC on August 21, 2020, as amended on September 2, 2020, registering an indeterminate number or amount of Ordinary shares, preference shares, debt securities, rights, warrants and units of the Company, or the equivalent thereof in foreign currencies or currency units, or if any debt securities are issued with original issue discount, in all cases not to exceed an aggregate offering price of $200,000,000.

     

     

    5.

    Registration Statement on Form S-3 (File No. 333-235508), originally filed with the SEC on December 13, 2019, registering 105,000 Ordinary Shares.

     

     

    6.

    Registration Statement on Form S-3 (File No. 333-226800), originally filed with the SEC on August 13, 2018, registering an indeterminate number or amount of Ordinary shares, preference shares, debt securities, rights, warrants and units of the Company, or the equivalent thereof in foreign currencies or currency units, or if any debt securities are issued with original issue discount, in all cases not to exceed an aggregate offering price of $200,000,000.

     

     

    7.

    Registration Statement on Form S-3 (File No. 333-221470), originally filed with the SEC on November 9, 2017, registering up to 16,829,366 Ordinary Shares and certain related warrants (which ae exercisable into the Ordinary Shares).

     

     

    8.

    Registration Statement on Form S-3 (File No. 333-203818), originally filed with the SEC on May 1, 2015, registering up to 2,789,614 Ordinary Shares (including 850,000 warrant shares issuable upon exercise of the pre-funded warrants). 

     

    On January 10, 2023 (the “Petition Date”), Quotient filed the Prepackaged Chapter 11 Plan of Reorganization of Quotient Limited (as amended, modified or supplemented from time to time, the “Plan”) and the related disclosure statement (the “Disclosure Statement”) in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). On February 15, 2023, the Bankruptcy Court entered an order (the “Confirmation Order”) confirming the Plan, as modified by the Confirmation Order, and approving the Disclosure Statement. The Plan is attached to the Confirmation Order as Exhibit A. On February 16, 2023, the Plan became effective in accordance with its terms and the Company emerged from bankruptcy.

     

    Pursuant to the Plan, on March 2, 2023, the Company entered into a Merger Implementation Agreement by and among the Company, Quotient Holdings Merger Company Limited (“MergerCo”) and Quotient Holdings Finance Company Limited (“Finance Co”) (as amended from time to time, the “Merger Implementation Agreement”), pursuant to which, on June 9, 2023 (the “Closing Date”), the Company merged with MergerCo (the “Merger”).

     

    In furtherance of the Merger, the Registrant terminated all offerings of its securities pursuant to the Registration Statements and the Registrant hereby removes and withdraws from registration any and all securities of the Registrant registered pursuant to the Registration Statements that remain unsold or otherwise unissued as of the date hereof.  The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.

     

     

     

     

     

     

    SIGNATURES

     

     

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on June 26, 2023.

     

     

     

     

    QUOTIENT LIMITED

     
           
     

    By:

    /s/ Manuel O. Méndez

     
       

    Manuel O. Méndez

     
       

    Chief Executive Officer

     

     

     

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the specified registration statements on Form S-3.

     

     
    Get the next $QTNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTNT

    DatePrice TargetRatingAnalyst
    12/3/2021$4.00 → $3.50Neutral
    Goldman Sachs
    8/6/2021$5.00 → $4.50Neutral
    Goldman Sachs
    More analyst ratings

    $QTNT
    Financials

    Live finance-specific insights

    See more
    • Quotient Limited Provides First Quarter Fiscal 2023 Results and Business Update

      MosaiQ™ Solution Commercial Execution: Extended IH Launch: $1.4 million MosaiQ bookings completed with $0.4 million in revenue in the first quarterDistribution Network: Ten agreements signed with more in process; First distributor network meeting held in Switzerland with 12 participantsTenders: The Company continues to actively participate in and prepare for all available tenders Transfusion Diagnostics: Extended Immunohematology (IH) microarray on track for US FDA submission by year-end; Extended Serological Disease Screening (SDS) microarray panel on-track for EU commercial launch in calendar year 2023; InfYnity partnership enriches infectious disease immunoassay microarray offeringClinica

      8/9/22 7:00:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9th

      JERSEY, Channel Islands, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022. Title:Quotient First Quarter Fiscal 2023 Financial Results and Conference Call Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial OfficerDate:Tuesday, August 9, 2022Time:8:30am ET/ 14:30 CETConference Call Dial-in Details:International: 201-689-8560Switzerland: 0800 835 525United Kingdom: 0800 756 3429US: 877-407-0784Conference ID: 13731396Webcast:Webcast Link - Click HereQuot

      8/2/22 4:05:00 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update

      Financial Position Amended Secured Notes: Reduces the company's cash obligations by approximately $93 million over the next 36 monthsAnnounces Public Equity Offering: Improving liquidity runwayFY 2022 Revenue of $38.5 Million$83.2 million in cash and investments as of March 31, 2022  MosaiQ™ Solution Commercial Execution: Extended IH Launch: Commercialization is underway; $1.4 million of MosaiQ orders in Q1 FY2023; Multiple MosaiQ instruments shipped to customersTenders: Actively engaged in Immunohematology (IH) donor tenders; 20 European IH donor tender submissions expected in the next 18 monthsDistribution Network: 9 international agreements in place and expanding global distribution ne

      6/24/22 7:00:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quotient Limited Announces Intent to Voluntary Delist from the Nasdaq Global Market

      JERSEY, Channel Islands, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company") today announced that it has given formal notice to the Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market. In order to implement the delisting, the Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") on or about December 27, 2022. The delisting of the Company's ordinary shares will take effect no earlier than ten days after the date of that Form 25 filing. The Company expects that as a result of this voluntary delisting, the last trading day of its ordinary shares on the Nasda

      12/12/22 4:05:00 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Reverse Stock Split Effective Today

      JERSEY, Channel Islands, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that a reverse split of its ordinary shares, nil par value ("Ordinary Shares"), at a ratio of 1-for-40 became effective following close of trading on the Nasdaq Global Market today. The Company's Ordinary Shares will begin trading on a split-adjusted basis when the market opens on November 3, 2022 under the existing trading symbol, "QTNT." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Global Market. The new CUSIP

      11/2/22 5:01:00 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Intent to Effect Reverse Stock Split

      JERSEY, Channel Islands, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that it will effect a one-for-40 reverse stock split ("Reverse Stock Split") of its ordinary shares, nil par value ("Ordinary Shares") that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market ("Nasdaq"). The Company's Ordinary Shares are expected to begin trading on a split-adjusted basis when the market opens on November 3, 2022 on the Nasdaq under the existing symbol "QTNT." The Reverse Stock Split is primarily intended to bring the Company into compliance

      10/31/22 6:30:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Quotient Limited

      15-12G - Quotient Ltd (0001596946) (Filer)

      6/30/23 7:56:39 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Quotient Limited

      EFFECT - Quotient Ltd (0001596946) (Filer)

      6/30/23 12:15:07 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Quotient Limited

      EFFECT - Quotient Ltd (0001596946) (Filer)

      6/30/23 12:15:20 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Quotient Holdings Gp, Llc claimed ownership of 17,020,000 shares

      3 - Quotient Ltd (0001596946) (Issuer)

      2/27/23 4:51:06 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 17,247,931 units of Ordinary Shares

      3 - Quotient Ltd (0001596946) (Issuer)

      2/27/23 4:05:35 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Hallsworth Frederick converted options into 438 units of Ordinary Shares, increasing direct ownership by 8% to 6,186 units

      4 - Quotient Ltd (0001596946) (Issuer)

      2/2/23 8:30:35 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman Sachs reiterated coverage on Quotient with a new price target

      Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $3.50 from $4.00 previously

      12/3/21 9:07:16 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Goldman Sachs reiterated coverage on Quotient with a new price target

      Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $4.50 from $5.00 previously

      8/6/21 8:50:59 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Goldman Sachs initiated coverage on Quotient with a new price target

      Goldman Sachs initiated coverage of Quotient with a rating of Neutral and set a new price target of $5.00

      6/3/21 6:30:51 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Quotient Limited

      SC 13D - Quotient Ltd (0001596946) (Subject)

      2/27/23 4:14:00 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Quotient Limited (Amendment)

      SC 13D/A - Quotient Ltd (0001596946) (Subject)

      2/22/23 10:45:07 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Quotient Limited (Amendment)

      SC 13D/A - Quotient Ltd (0001596946) (Subject)

      2/21/23 5:03:18 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO

      Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sanno

      10/26/22 7:05:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Appointment of New Board Member

      JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to Quotient Board of Directors effective as of May 1, 2022. Mr. Aebischer will also serve on the Board's Audit Committee. "We are delighted to welcome Mr. Aebischer to the Quotient Board," said Heino von Prondzynski, Chairman of Quotient's Board of Directors. "Thomas brings decades of experience in global financial and capital markets and a highly strategic mindset. We are very fortunate to have him by our side as we continue to grow our business and drive the value of our revolutionary diagnostic solutions.

      4/26/22 8:30:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Appointment of Chief Manufacturing Operations Officer

      JERSEY, Channel Islands, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mr. Esteban Uriarte as the Company's Chief Manufacturing Operations Officer (CMOO). Mr. Uriarte will assume the responsibilities of CMOO on February 1st, 2022. "It is my pleasure to welcome Esteban to the Executive team at this exciting time in our Company's evolution. Esteban brings his experience in leading high-growth teams and unifying manufacturing and supply chain management. As we transition the company from the development phase into commercialization, we will drive scale up in manufacturing to transform the business," said Manuel O. Mé

      11/30/21 8:30:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care